News | February 06, 2021
Pfizer registers Q3FY21 PAT at Rs. 141.24 Cr
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
The commercial production in the SML was started in November 1989.
Subscribe To Our Newsletter & Stay Updated
